MIM
ABUS icon

MetLife Investment Management’s Arbutus Biopharma ABUS Stock Holding History

MetLife Investment Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$453K Buy
94,351
+13,282
+16% +$58.3K ﹤0.01% 1965
2026
Q1 		$365K Buy
81,069
+7,833
+11% +$34.3K ﹤0.01% 1907
2025
Q4 		$352K Sell
73,236
-14,614
-17% -$65.7K ﹤0.01% 1962
2025
Q3 		$399K Sell
87,850
-916
-1% -$3.36K ﹤0.01% 1919
2025
Q2 		$274K Sell
88,766
-121
-0.1% -$402 ﹤0.01% 2011
2025
Q1 		$310K Buy
88,887
+7,235
+9% +$24.1K ﹤0.01% 1956
2024
Q4 		$267K Sell
81,652
-59
-0.1% -$217 ﹤0.01% 2148
2024
Q3 		$315K Hold
81,711
– – ﹤0.01% 2041
2024
Q2 		$252K Buy
81,711
+19,839
+32% +$59.5K ﹤0.01% 2101
2024
Q1 		$160K Buy
61,872
+2,891
+5% +$7.49K ﹤0.01% 2315
2023
Q4 		$147K Hold
58,981
– – ﹤0.01% 2404
2023
Q3 		$120K Hold
58,981
– – ﹤0.01% 2491
2023
Q2 		$136K Hold
58,981
– – ﹤0.01% 2505
2023
Q1 		$179K Buy
58,981
+14,846
+34% +$41.9K ﹤0.01% 2284
2022
Q4 		$103K Sell
44,135
-14,321
-24% -$34.3K ﹤0.01% 2584
2022
Q3 		$112K Buy
58,456
+23,312
+66% +$54.9K ﹤0.01% 2629
2022
Q2 		$95.2K Sell
35,144
-4,484
-11% -$11.5K ﹤0.01% 2730
2022
Q1 		$118K Buy
39,628
+29,648
+297% +$90.8K ﹤0.01% 2595
2021
Q4 		$38.8K Sell
9,980
-20,062
-67% -$77.9K ﹤0.01% 2471
2021
Q3 		$129K Buy
+30,042
New +$100K ﹤0.01% 2328
2018
Q4 		– Sell
-18,578
Closed -$176K – 2568
2018
Q3 		$176K Buy
+18,578
New +$184K ﹤0.01% 2157

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

MetLife Investment Management's ABUS Position: Q2 2026 in Review

MetLife Investment Management increased its Arbutus Biopharma (ABUS) stake by 16% in Q2 2026, buying an estimated $58.3K and bringing the position to 94,351 shares worth $453K. The position accounts for ﹤0.01% of the portfolio, ranked #1965.

MetLife Investment Management first reported a position in ABUS in Q3 2018 and has held it in 21 quarters since. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • MetLife Investment Management held 94,351 shares of Arbutus Biopharma worth $453K as of Q2 2026.
  • MetLife Investment Management bought 13,282 Arbutus Biopharma shares in Q2 2026, an estimated $58.3K.
  • Arbutus Biopharma made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1965 holding.
  • MetLife Investment Management first reported a position in Arbutus Biopharma in Q3 2018 and has held it in 21 quarters since.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.